849217-60-3

Basic information

• Product Name: N-(4-fluorophenyl)-N-(4-hydroxyphenyl)cyclopropane-1,1-dicarboxamide
• Synonyms: N-(4-fluorophenyl)-N-(4-hydroxyphenyl)cyclopropane-1,1-dicarboxamide;Cyclopropane-1,1-dicarboxylic acid N-(4-fluorophenyl)amide N'-(4-hydroxyphenyl)amide;cyclopropane-1,1-dicarboxylic acid (4-fluoro-phenyl)-amide (4-hydroxy-phenyl)-amide
• CAS NO: 849217-60-3
• Molecular Formula: C₁₇H₁₅FN₂O₃
• Molecular Weight: 314.3110032
• Mol File: 849217-60-3.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 639.7±50.0 °C(Predicted)
• Appearance: /
• Density: 1.486±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 10.11±0.26(Predicted)
• CAS DataBase Reference: N-(4-fluorophenyl)-N-(4-hydroxyphenyl)cyclopropane-1,1-dicarboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-fluorophenyl)-N-(4-hydroxyphenyl)cyclopropane-1,1-dicarboxamide(849217-60-3)
• EPA Substance Registry System: N-(4-fluorophenyl)-N-(4-hydroxyphenyl)cyclopropane-1,1-dicarboxamide(849217-60-3)

Safety Data

• Hazardous Substances Data: 849217-60-3(Hazardous Substances Data)

Usage

Uses

N-(4-Fluorophenyl)-N''-(4-hydroxyphenyl)-1,1-cyclopropanedicarboxamide can be used to treat kinase-dependenet disorders.

Upstream product

• 113020-21-6 1,1-cyclopropanedicarboxylic acid monomethyl ester 
• 123-30-8 4-amino-phenol 
• 1345847-71-3 methyl 1-((4-fluorophenyl)amidomethyl)cyclopropyl-1-carboxylate 
• 6914-71-2 dimethyl 1,1-cyclopropanedicarboxylate 
• 849217-48-7 ((4-fluorophenyl)carbamoyl)cyclopropanecarboxylic acid 
• 208121-91-9 1-[(4-fluorophenyl)amido]cyclopropanecarboxylic acid 
• 371-40-4 4-fluoroaniline 
• 598-10-7 cyclopropane-1,1-dicarboxylic acid 

Downstream Products

• 849217-68-1 cabozantinib 

Relevant articles and documents

Structure-guided design and development of novel N-phenylpyrimidin-2-amine derivatives as potential c-Met inhibitors

The HGF/Met signaling pathway is over-expressed in many types of cancers and closely related to oncogenesis and metastasis. Thus, we developed novel N-phenylpyrimidin-2-amine derivatives to test their inhibitory activities towards c-Met kinase, and most o

COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS

Disclosed herein are compounds of Formula (I) which inhibit, regulate and/or modulate tyrosine kinase receptors, particularly Axl and Mer signal transduction pathways related to the changes in cellular activities, compositions containing the compounds, methods of using the compounds to treat kinase-dependent diseases and conditions, and methods for making the compounds.

Synthesis and anti-tumor activity of [1,4] dioxino [2,3-f] quinazoline derivatives as dual inhibitors of c-Met and VEGFR-2

Both c-Met and VEGFR-2 were important targets for cancer therapies. In order to develop reversible and non-covalent c-Met and VEGFR-2 dual inhibitors, a series of [1,4]dioxino[2,3-f]quinazoline derivatives were designed and synthesized. The enzyme assay demonstrated that most target compounds had inhibition potency on both c-Met and VEGFR-2 with IC50 values in nanomolar range especially compounds 7m and 7k. Based on further cell proliferation assay in vitro, compound 7k showed significantly anti-tumor activity in vivo on a hepatocellular carcinoma (MHCC97H cells) xenograft mouse model. We docked the compound 7m with c-Met and VEGFR-2 kinases, and interpreted the SAR of these analogues. All results indicated that the target compounds were dual inhibitors of c-Met and VEGFR-2 kinases that held promising potential in cancer therapy.